Evidence map›Paper›PMID 40361560›Full record

ArticleFoods (Basel, Switzerland)2025

Zhengnan Ren, Yikuan Wu, Xiaoying Guo, Haizhi Tian, Hongjing Ou, Zihan Xiong, Yu Xiao, Longquan Xiao, Jing Li, Haibo Wu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Foods (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhengnan RenCollege of Food and Biological Engineering, Chengdu University, Chengdu 610106, China.ORCID 0000-0003-1271-5399
Yikuan WuInstitute of Science and Technology, Jiangnan University, Wuxi 214122, China.
Xiaoying GuoSichuan Kelun Pharmaceutical Co., Ltd., Chengdu 610599, China.
Haizhi TianSchool of Food Science and Technology, Jiangnan University, Wuxi 214122, China.
Hongjing OuCollege of Food and Biological Engineering, Chengdu University, Chengdu 610106, China.
Zihan XiongCollege of Food and Biological Engineering, Chengdu University, Chengdu 610106, China.
Yu XiaoCollege of Food and Biological Engineering, Chengdu University, Chengdu 610106, China.
Longquan XiaoCollege of Food and Biological Engineering, Chengdu University, Chengdu 610106, China.
Jing LiCollege of Food and Biological Engineering, Chengdu University, Chengdu 610106, China.
Haibo WuTurpan Institute of Agricultural Sciences, Xinjiang Academy of Agricultural Sciences, Turpan 838099, China.
Xinhui WangCollege of Food and Biological Engineering, Chengdu University, Chengdu 610106, China.

Funding

Industry-Education Deep Integration Reform Pilot Project of Sichuan Province N/AJoint Fund for Science and Technology Education of Sichuan Province 2024NSFSC2067Natural Science Foundation of Jiangsu Province BK20231042Sichuan Science and Technology Program 2025ZNSFSC1056
6 · The paper itself

Abstract

Breast cancer remains one of the leading causes of cancer-related mortality among women worldwide. Although the mTOR inhibitor rapamycin exhibits notable anti-tumor activity, its clinical application is limited by metabolic side effects, particularly dyslipidemia. This study aimed to investigate the potential of

Indexed as

breast cancerdietary interventionIlex latifoliarapamycin

Identifiers

PMID40361560
PMCPMC12072097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.